Senti Biosciences, Inc. (SNTI)

NASDAQ: SNTI · Real-Time Price · USD
3.430
+0.104 (3.14%)
At close: Mar 28, 2025, 4:00 PM
3.440
+0.010 (0.29%)
After-hours: Mar 28, 2025, 7:56 PM EDT
3.14%
Market Cap 89.19M
Revenue (ttm) n/a
Net Income (ttm) -55.31M
Shares Out 26.00M
EPS (ttm) -12.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 9,036
Open 3.400
Previous Close 3.326
Day's Range 3.340 - 3.630
52-Week Range 1.520 - 16.940
Beta 2.53
Analysts Strong Buy
Price Target 12.00 (+249.85%)
Earnings Date Mar 20, 2025

About SNTI

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing t... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 34
Stock Exchange NASDAQ
Ticker Symbol SNTI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for SNTI stock is "Strong Buy" and the 12-month stock price forecast is $12.0.

Price Target
$12.0
(249.85% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights

– Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical trial of SENTI-202 maintaining remission –        – Stren...

10 days ago - GlobeNewsWire

Senti Bio Appoints Feng Hsiung to Board of Directors

– Company also announced inducement grants under Nasdaq Listing Rule 5635(c)(4) – – Company also announced inducement grants under Nasdaq Listing Rule 5635(c)(4) –

17 days ago - GlobeNewsWire

Senti Bio Strengthens Leadership Team with Strategic Hires

– Jay Cross, proven financial leader, appointed as CFO to drive strategic growth – – Faraz Siddiqui, expert in manufacturing operations, joins as SVP Technical Operations – SOUTH SAN FRANCISCO, Calif....

4 weeks ago - GlobeNewsWire

Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics

– Dose-finding clinical trial in China designed to evaluate safety and preliminary anti-tumor activity of SN301A (SENTI-301A manufactured in China) in hepatocellular carcinoma (“HCC”) –

3 months ago - GlobeNewsWire

Senti Biosciences Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene the...

4 months ago - GlobeNewsWire

Why Is Senti Biosciences Stock Surging Over 400% On Monday?

Senti Biosciences, Inc. SNTI stock is skyrocketing on Monday, with a strong session volume of 73.4 million compared to an average volume of 17.81 thousand, as per data from Benzinga Pro.

4 months ago - Benzinga

Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation ...

4 months ago - GlobeNewsWire

Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML

– 2 of 3 patients achieved MRD negative CR in the first dose level evaluated in the trial with a generally well-tolerated preliminary safety profile –

4 months ago - GlobeNewsWire

Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights

Enrollment continues in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML; initial clinical data expected in Q4 2024 Enrollment contin...

4 months ago - GlobeNewsWire

Senti Bio to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a biotechnology company developing next-generation cell and gene ...

7 months ago - GlobeNewsWire

Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights

– Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML –

8 months ago - GlobeNewsWire

Senti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing next-generation cell and gene therapies using it...

8 months ago - GlobeNewsWire

Senti Bio Announces Reverse Stock Split

Shares expected to begin trading on split-adjusted basis on July 18, 2024 Shares expected to begin trading on split-adjusted basis on July 18, 2024

9 months ago - GlobeNewsWire

Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy

SOUTH SAN FRANCISCO, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing next-generation cell and gene therapies using it...

9 months ago - GlobeNewsWire

Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia

– SENTI-202 is a potential first-in-class Logic Gated off-the-shelf CAR-NK cell therapy – – Initial clinical efficacy data expected by year-end 2024 and durability data expected in 2025 – SOUTH SAN FR...

11 months ago - GlobeNewsWire

Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights

– First patient dosing of SENTI-202, a first-in-class logic-gated treatment for acute myeloid leukemia (“AML”), on track for the second quarter of 2024 – SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLO...

11 months ago - GlobeNewsWire

Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)

– Preclinical data demonstrates the potential for improved treatment outcomes and reduced toxicity for patients with AML – – Data supports the design of Phase 1 clinical trial of SENTI-202 with patien...

11 months ago - GlobeNewsWire

Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights

– IND for SENTI-202, a potential first-in-class logic-gated treatment for AML, cleared by the U.S. FDA; First patient dosing anticipated in the second quarter of 2024 –

1 year ago - GlobeNewsWire

Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program

– Strategic resource allocation to focus investment on clinical development of SENTI-202 and SENTI-301A partnership in China; interim data from Phase 1 clinical trial of SENTI-202 expected in 2H 2024 ...

1 year ago - GlobeNewsWire

Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia

– First patient in Phase 1 clinical trial expected to be treated in Q2 2024 – – Initial clinical efficacy data expected by year-end 2024 and durability data expected in 2025 – – SENTI-202 is a potenti...

1 year ago - GlobeNewsWire

Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates

– IND for SENTI-202, a potential first-in-class logic-gated treatment for cancer, on track for clearance in Q4 2023 –

1 year ago - GlobeNewsWire

Week In Review: Eccogen Out-Licenses GLP-1 Agonist To AstraZeneca In $2 Billion Deal

Eccogene out-licenses global rights for its GLP-1 agonist to AstraZeneca in a $2 billion deal. Biotheus sells ex-China rights for a bispecific antibody candidate to BioNTech for $55 million upfront. W...

Other symbols: AZNBNTXBSX
1 year ago - Seeking Alpha

Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China

– Celest to lead clinical development with technical support from Senti Bio – – First patient expected to be enrolled in China in 1H 2024 – – Senti Bio eligible to receive up to $156 million in milest...

1 year ago - GlobeNewsWire

Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting

– Two poster presentations highlighting new preclinical data with BlueRock Therapeutics – – Two poster presentations showcasing Senti Bio's proprietary Gene Circuit platform – SOUTH SAN FRANCISCO, Cal...

1 year ago - GlobeNewsWire

Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting

- Four abstracts highlight Gene Circuit platforms that enhance the scope, precision, effectiveness, and controllability of oncology cell therapies -

1 year ago - GlobeNewsWire